The difference of not using TCR replacement was also apparent using primary CD8+ T cells, as such cells were unable to respond to cancer targets while TCR-replaced CD8+ T cells gave robust responses in parallel (P ≤ 0.05 and 0.001, depending on assay). Here, CD8A is linked to cancer.